Biggest News Aggregation in the World
📰 Paper Texture News

Paper Texture News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Paper Texture. Real-time updates on events, politics, business and more.

FDA Approves Belzutifan for Advanced RCC After PD-1 or PD-L1 Inhibition and a VEGF-TKI

The approval of belzutifan, an oral hypoxia-inducible factor-2 alpha inhibitor, provides a new option for patients with advanced renal cell carcinoma (RCC) following treatment with a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).
Tonik Choueiri Merck Welireg Lank Center Dana Farber Cancer Institute Genitourinary Cancer At Dana Farber Institute Paper Texture
Source: ajmc.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science